• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Int J Cardiol Heart Vasc . Circulating angiogenic progenitor cell apoptosis in Post-COVID-19 syndrome

tetano

Editor, Senior Moderator
Int J Cardiol Heart Vasc


. 2026 Jan 8:62:101866.
doi: 10.1016/j.ijcha.2025.101866. eCollection 2026 Feb.
Circulating angiogenic progenitor cell apoptosis in Post-COVID-19 syndrome

Julia M Kröpfl[SUP] 1 [/SUP], Christoph Hauser[SUP] 1 [/SUP], Luca Beugger[SUP] 1 [/SUP], Henner Hanssen[SUP] 1 [/SUP], Fabian Schwendinger[SUP] 1 [/SUP], Arno Schmidt-Trucksäss[SUP] 1 [/SUP]


Affiliations
Abstract

Background: Cellular endothelial dysfunction in patients recovering from Coronavirus disease 2019 (COVID-19) remains poorly understood. This study examined circulating angiogenic progenitor cells (CAC) and mature endothelial cells (CEC) in individuals with persistent symptoms following hospitalization for COVID-19 (PH-PCS) at ≥ 18-months post-infection.
Methods: We compared PH-PCS (n = 14) to matched controls without symptomatic COVID-19 (n = 7). Examinations included macro- and microvascular structure and function and the analysis of CAC and CEC using flow cytometry.
Results: Estimates indicated somewhat lower apoptotic CAC concentrations (mean difference[md] [95 %CI] = 0.050 cells/µl [0.003, 0.137], p = 0.084) and proportions (% total CAC, 7.7 percentage points (pp) [0.3, 12.9], p = 0.066) in patients compared to controls, though estimates were imprecise. Similar results were observed for apoptotic CEC concentrations (1.202 cells/µl [0.040, 7.518], p = 0.066) and proportions (% total CEC, 2.7 pp [0.2, 23.8], p = 0.048). Live CAC (-7.6 pp [-12.7, -1.1], p = 0.084) and live CEC proportions (-4.9 pp [-23.7, -0.3], p = 0.042) were somewhat enhanced in PH-PCS. Brachial-arterial flow-mediated dilation (baFMD) and retinal vessel imaging parameters showed little evidence for differences between groups, except for maximal arteriolar constriction, where estimates suggested on average higher values in PH-PCS (md [95 %CI] = 1.64 [0.050, 3.63], p = 0.084), but estimates were uncertain. Pooling PH-PCS and controls, correlations were observed between reduced baFMD and both elevated total CEC concentrations (ρ = -0.56, p = 0.038) and decreased apoptotic CAC proportions (ρ = 0.56, p = 0.042).
Conclusions: This study suggests the possibility of unbalanced CAC and CEC apoptosis in PH-PCS, but with uncertain magnitude. The findings might inform hypothesis generation for future studies on (cellular) endothelial function in PH-PCS.

Keywords: Circulating progenitor cell; Flow-mediated dilation; Long-COVID; Post-COVID-19 syndrome; Retinal vessel analysis.

 
Back
Top